Skip to content
Menu

Palvella Therapeutics, Inc. PVLA

Full chart Compare
Set alert

Price alert · PVLA

All alert types
142.85 USD -2.92 (-2.00%)

Regular-session close

142.85 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

142.22 Day range 148.69
76.43 52-week range 175.92
YTD
+36.48%
1 year
+56.05%

5D -14.14 (-9.01%)

140145150155MonTueWedThuFri142.85
Market cap
2.09B
EPS (ttm)
-5.53
Shares out
14.62M
Forward P/E
-18.77
YTD return
+36.48%
1-year return
+56.05%
50-day average
142.96
200-day average
131.76
Enterprise value
1.92B
Volume
192.67K
Avg volume
239.93K
Open
143.10
Previous close
145.77
Day's range
142.22 – 148.69
52-week range
76.43 – 175.92
Analysts
Strong Buy
Price target
233.44 (+63.4%)
Earnings date
Mar 30, 2027

Key statistics

Price / book
10.54
Free cash flow
-27.99M
Total cash
236.68M
Total debt
25.41M
Return on equity
-63.39%
Short % of float
20.11%

Fundamental scorecard

3 of 25 checks passed on PVLA’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PVLA Revenue — quarterly 0
PVLA Net income — quarterly -24.64M
PVLA EPS — quarterly -1.70

Earnings

PVLA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 30, 2027Dec 30, 2026-1.95———
Nov 5, 2026Sep 30, 2026-1.78-1.70+0.08+4.49%
Aug 4, 2026Jun 30, 2026-1.17-1.52-0.35-29.91%
May 7, 2026Mar 31, 2026-0.90-1.20-0.30-33.33%
Mar 31, 2026Dec 31, 2025-0.91117-1.08-0.17-18.53%
Nov 11, 2025Sep 30, 2025-0.85-1.03-0.18-21.18%

Upgrades / downgrades

PVLA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026Canaccord GenuitymainBuyBuy
Nov 6, 2026OppenheimermainOutperformOutperform
Oct 28, 2026Chardan CapitalmainBuyBuy
Oct 16, 2026William Blairinit—Outperform
Oct 12, 2026HC Wainwright & Co.mainBuyBuy
Sep 21, 2026Chardan CapitalmainBuyBuy

About Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PVLA — it syncs with the Stock Master app.

Insider holders

PVLA insider holders
InsiderRelationLatest transactionDateShares held
GOIN KATHLEENChief Operating OfficerSaleAug 18, 20260
HERON ELAINE JDirectorPurchaseFeb 26, 202653,691
JENKINS GEORGE MDirectorSaleOct 13, 2026146,132
KIRITSY CHRISTOPHER PDirectorSaleSep 1, 2026250
KORENBERG MATTHEW EChief Financial OfficerConversion of Exercise of derivative securityJun 11, 20261,000
MARTINI JEFFREYOfficerSaleNov 10, 20260

Institution ownership

PVLA institution ownership
Holder% heldSharesValueReported
Jennison Associates LLC7.54%1,101,652157.37MSep 29, 2026
Montanova Capital LLC7.15%1,044,898149.26MSep 29, 2026
Blackrock Inc.6.77%989,691141.38MSep 29, 2026
Frazier Life Sciences Management, L.P. 6.04%882,400126.05MSep 29, 2026
First Light Asset Management, LLC5.02%734,086104.86MSep 29, 2026
State Street Corporation4.27%624,87989.26MSep 29, 2026

Fund ownership

PVLA fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.66%388,39055.48MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.48%362,31451.76MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.11%308,69944.10MSep 29, 2026
Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund1.89%276,55639.51MJul 30, 2026
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund1.58%231,48433.07MJun 29, 2026
PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund1.45%212,22530.32MSep 29, 2026